25 July 2017
Reporter: Mark Dugdale

Amphastar dodges hefty damages award

Amphastar Pharmaceuticals has sidestepped a potential $900 million payout after a District of Massachusetts jury invalidated the patent asserted against it.

Momenta Pharmaceuticals and Sandoz claimed that Amphastar's testing of its generic enoxaparin sodium blood thinner infringed their patent, but on 21 July the US District Court for the District of Massachusetts jury found it invalid for lack of enablement and adequate written description.

The pharmaceutical companies demanded more than $900 million in damages when they filed the patent infringement suit in 2011.

After the two-week trial, the jury also found that Momenta and Sandoz had waived their ability to enforce the patent against Amphastar due to their inequitable conduct before the US Pharmacopeial Convention.

Craig Wheeler, president and CEO of Momenta, said the company is considering launching an appeal.

“We are disappointed in the jury's verdict and believe the facts and the law do not support these findings. We are considering all available legal options to overturn the verdict, including post-trial motions and appeals,” said Wheeler.

“We continue to believe in the importance of investing in innovative techniques for bringing products to market and protecting those innovations from unauthorised use.”

Amphastar CEO Dr Jack Zhang said: “We have always believed that the facts and the law do not support the plaintiffs’ baseless allegations and we are very pleased that justice has prevailed. We remain proud of our technology for product development and will continue to execute on our mission of developing and manufacturing life-saving drugs for the benefit of patients.”

More news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
USPTO unveils new filing system
15 December 2017 | Washington DC | Reporter: Barney Dixon
The US Patent and Trademark Office (USPTO) has unveiled a new filing system that will launch in 2018 and be fully implemented by 2019
Innovation has thrived under AIA, according to tech association
14 December 2017 | Washington DC | Reporter: Barney Dixon
The High Tech Investors Alliance has responded to contentions that recent legislation and US Supreme Court decisions, including the Alice Corp v CLS Bank case, have weakened the US patent system
Patent perception must shift, says Schecter
13 December 2017 | London | Reporter: Barney Dixon
Public perception must shift if the US is to find feasible solutions to patent abuse, according to chief patent counsel at IBM Manny Schecter
Patent owners winning in IPR
12 December 2017 | New York | Reporter: Barney Dixon
Patent owners are winning more than losing in IPR proceedings, according to a study from law firm Fitzpatrick, Cella, Harper & Scinto
High tech companies weigh in on Allergan deal
11 December 2017 | Washington DC | Reporter: Barney Dixon
Tech companies have argued that Allergan should not be allowed to circumvent the inter partes review process with its controversial patent deal with the Saint Regis Mohawk Tribe
BlackBerry to pay $137 million to Nokia
08 December 2017 | Waterloo | Reporter: Barney Dixon
BlackBerry will pay $137 million to Nokia after the International Chamber of Commerce’s International Court of Arbitration ruled against the company in a patent licensing dispute
ILO ruling “vote of no confidence” for Battistelli, says CSC
07 December 2017 | Munich | Reporter: Barney Dixon
In an open letter to the EPO’s heads of delegations, the CSC said that it interpreted the ILO’s decision as a “massive vote of no confidence in the president of the EPO"